Travere Therapeutics (NASDAQ:TVTX) Shares Down 4.2% – Should You Sell?

Travere Therapeutics, Inc. (NASDAQ:TVTX) shares traded down 4.2% during trading on Tuesday . The company traded as low as $17.81 and last traded at $17.81. 88,018 shares were traded during mid-day trading, a decline of 92% from the average session volume of 1,071,796 shares. The stock had previously closed at $18.59.

Wall Street Analyst Weigh In

A number of research analysts have issued reports on the company. Citigroup decreased their price target on Travere Therapeutics from $23.00 to $19.00 and set a “buy” rating for the company in a report on Friday, September 27th. Guggenheim boosted their target price on shares of Travere Therapeutics from $23.00 to $41.00 and gave the company a “buy” rating in a research note on Wednesday, October 9th. Wells Fargo & Company upgraded shares of Travere Therapeutics from an “equal weight” rating to an “overweight” rating and raised their price target for the company from $9.00 to $27.00 in a research report on Monday, October 21st. Canaccord Genuity Group lowered their target price on shares of Travere Therapeutics from $23.00 to $22.00 and set a “buy” rating on the stock in a research note on Monday, September 30th. Finally, Wedbush lifted their price target on Travere Therapeutics from $17.00 to $25.00 and gave the company an “outperform” rating in a research note on Wednesday, October 9th. One research analyst has rated the stock with a hold rating and twelve have assigned a buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $23.67.

Travere Therapeutics Stock Performance

The company has a debt-to-equity ratio of 24.96, a quick ratio of 1.68 and a current ratio of 1.71. The firm’s 50-day moving average price is $18.22 and its two-hundred day moving average price is $14.28. The stock has a market cap of $1.36 billion, a price-to-earnings ratio of -3.82 and a beta of 0.70.

Travere Therapeutics (NASDAQ:TVTX) last posted its quarterly earnings results on Thursday, October 31st. The company reported ($0.70) earnings per share for the quarter, beating the consensus estimate of ($0.71) by $0.01. Travere Therapeutics had a negative net margin of 172.75% and a negative return on equity of 537.74%. The business had revenue of $62.90 million during the quarter, compared to analysts’ expectations of $60.87 million. During the same quarter in the prior year, the company posted ($1.17) EPS. The business’s revenue for the quarter was up 69.6% on a year-over-year basis. On average, analysts expect that Travere Therapeutics, Inc. will post -3.94 EPS for the current fiscal year.

Insider Transactions at Travere Therapeutics

In other Travere Therapeutics news, CAO Sandra Calvin sold 15,000 shares of the stock in a transaction that occurred on Thursday, December 26th. The shares were sold at an average price of $17.22, for a total value of $258,300.00. Following the transaction, the chief accounting officer now directly owns 54,927 shares in the company, valued at $945,842.94. This represents a 21.45 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Jula Inrig sold 2,066 shares of the business’s stock in a transaction that occurred on Friday, January 3rd. The stock was sold at an average price of $19.10, for a total transaction of $39,460.60. Following the sale, the insider now owns 59,883 shares of the company’s stock, valued at $1,143,765.30. This represents a 3.34 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 29,596 shares of company stock valued at $527,262. 3.75% of the stock is currently owned by company insiders.

Institutional Trading of Travere Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in TVTX. Diversified Trust Co lifted its stake in Travere Therapeutics by 27.5% in the fourth quarter. Diversified Trust Co now owns 14,701 shares of the company’s stock valued at $256,000 after buying an additional 3,169 shares during the last quarter. Virtu Financial LLC acquired a new position in Travere Therapeutics in the third quarter valued at $301,000. Geode Capital Management LLC raised its holdings in shares of Travere Therapeutics by 3.9% in the third quarter. Geode Capital Management LLC now owns 1,731,045 shares of the company’s stock valued at $24,222,000 after buying an additional 64,744 shares during the last quarter. Two Sigma Advisers LP raised its stake in Travere Therapeutics by 30.2% during the 3rd quarter. Two Sigma Advisers LP now owns 720,400 shares of the company’s stock valued at $10,078,000 after acquiring an additional 167,100 shares during the last quarter. Finally, Quarry LP purchased a new position in shares of Travere Therapeutics in the 3rd quarter valued at approximately $105,000.

About Travere Therapeutics

Travere Therapeutics, Inc, a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.